Shanghai Junshi Biosciences Co., Ltd. (OTCMKTS:SHJBF – Get Free Report) was the target of a large growth in short interest during the month of October. As of October 30th, there was short interest totaling 82,400 shares, a growth of 41,100.0% from the October 15th total of 200 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.
Shanghai Junshi Biosciences Stock Performance
Shares of Shanghai Junshi Biosciences stock remained flat at C$3.35 during trading on Tuesday. Shanghai Junshi Biosciences has a 12-month low of C$2.99 and a 12-month high of C$4.23. The company’s 50-day moving average price is C$3.35 and its 200-day moving average price is C$3.22.
Shanghai Junshi Biosciences Company Profile
Shanghai Junshi Biosciences is a biopharmaceutical company founded in 2012 and headquartered in Shanghai, China. It develops innovative medicines, with research programs spanning oncology, autoimmune and metabolic diseases, and infectious diseases. The company’s best-known product is toripalimab, an anti-PD-1 antibody marketed in China as Tuoyi and in the United States as Loqtorzi. It is used for certain cancers, including nasopharyngeal carcinoma. Junshi also develops a pipeline of antibody-based and other therapies at different stages of research and clinical development.
Further Reading
- Five stocks we like better than Shanghai Junshi Biosciences
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Shanghai Junshi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shanghai Junshi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
